35 results
DEFM14A
SQZB
SQZ Biotechnologies Co
23 Jan 24
Proxy related to merger
4:31pm
industry, the continued execution of the strategy as a stand-alone company and/or a possible strategic or financial investment by a third party, including … information. As a result of its evaluation, the Board concluded that the Dissolution is the preferred strategy among the limited alternatives now
PREM14A
SQZB
SQZ Biotechnologies Co
12 Jan 24
Preliminary proxy related to merger
8:57am
strategic acquisition in the biotechnology industry, the continued execution of the strategy as a stand-alone company and/or a possible strategic or financial … and Dissolution” for additional information. As a result of its evaluation, the Board concluded that the Dissolution is the preferred strategy among
8-K
EX-2.1
SQZB
SQZ Biotechnologies Co
22 Dec 23
Entry into a Material Definitive Agreement
5:18pm
, meeting minutes and strategy materials); (c) all data, results and records of all studies, including the Laboratory Studies, Non-Clinical Studies
PRE 14A
7bo2fp3vub32z9g
10 Apr 23
Preliminary proxy
4:31pm
8-K
mbujghlxuy2f52 zeuw2
11 Jul 22
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
4:49pm
8-K
EX-99.2
40qioui
13 Sep 21
SQZ Biotechnologies Announces First Autoimmune Disease Indication
6:53am
DEF 14A
mg8okqsyl
26 Apr 21
Definitive proxy
5:00pm
10-K
864crdi3
18 Mar 21
Annual report
6:31am